We are proud to share that Biocytogen will be attending OTS 2025 Budapest from October 19th to the 22nd in Budapest, Hungary! Join us for an exciting experience full of networking opportunities, educational workshops on oligonucleotide therapeutics and RNA editing, alongside opportunities to demonstrate your research findings and technology in fire poster sessions. Have the opportunity to be in an event with over 900 experts, industry leaders, and scientists at every career stage that all strive to make a positive difference in life sciences. We hope to see you there.
What is OTS 2025 Budapest?
The OTS Annual Meeting serves as a key gathering for top researchers and industry leaders dedicated to advancing oligonucleotide therapeutics. This flagship event promotes collaboration and the exchange of cutting-edge knowledge across a broad spectrum of topics—from antisense and siRNA to immunostimulatory agents, aptamers, RNA/DNA editing, and mRNA-based therapies. Scientists at every career stage, from emerging researchers to seasoned experts, come together to share innovative research, engage in meaningful dialogue, and build valuable connections.
Event Overview
Date: October 19th-22nd, 2025
Venue: Budapest Congress Center. Budapest, Jagelló út 1-3, 1123 Hungary
Event Schedule
For a more in-depth overview of the agenda, please refer to OTS Agenda
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We look forward to seeing you at OTS 2025 Budapest!
